Table 2

Characteristics of T cells used for immunotherapy

Patient no.	Diagnosis	LN cell (no.)	Proliferation SEA/IL-2	%CD4/%CD8, initial	%CD4/%CD8, final	%CD25, final
1	Grade II astrocytoma	10× 10⁸	36×	66/11	ND^a	97
2	Grade II astrocytoma	11× 10⁸	51×	55/9	66/35	89
3	Anapl. mixed	4.9× 10⁸	30×	42/14	59/40	73
4	Anapl. oligodendroglioma	3.3× 10⁸	62×	63/8	64/33	ND
5	Anapl. ependymoma	1.4× 10⁸	75×	55/10	74/24	88
6	Anapl. astrocytoma	0.9× 10⁸	61×	56/6	62/22	58
7	Glioblastoma multiforme	6.5× 10⁸	54×	49/6	76/25	96
8	Glioblastoma multiforme	2.8× 10⁸	40×	45/12	70/29	96
9	Glioblastoma multiforme	2.9× 10⁸	33×	64/7	78/18	99
10	Glioblastoma multiforme	2.9× 10⁸	41×	62/8	77/17	94
11	Glioblastoma multiforme	2.3× 10⁸	42×	ND	81/20	98
12	Glioblastoma multiforme	1.6× 10⁸	19×^b	58/7	72/31	99

^a ND, not done; Anapl., anaplastic.
^b Final proliferation after additional OKT3 stimulation and IL-2 expansion was 71×.